News & Events

Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma

Cox Multivariate Regression Analysis for DMFS in All Stage III PatientsChicago, IL – June 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that three abstracts detailing results from studies of DecisionDx®-Melanoma were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6. Presentations included an interim analysis of a prospective, multicenter registry study, test performance in Stage III cutaneous (skin) melanoma patients and an analysis ... Read More

Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment of Castle Biosciences’ Uveal Melanoma Gene Expression Test

Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates ... Read More

Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma

Friendswood, TX – November 14, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. The data were presented in poster sessions at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, which was held ... Read More

Castle Biosciences Announces New Clinical Data to be Presented at ASCO 2016 Confirming Performance of DecisionDx-UM Gene Expression Profile (GEP) Test in Uveal Melanoma

Friendswood, TX—May 19, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new clinical data on DecisionDx®-UM, its gene expression profile (GEP) test to predict metastasis in patients diagnosed with uveal melanoma. The new data will be highlighted in a presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3-7. In a poster presentation titled, “A Prospective, Multi-Center Study ... Read More

Study Results with Castle Biosciences’ Uveal Melanoma Gene Expression Test Published in Journal of Oncology

Friendswood, TX—August 10, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of clinical data on DecisionDx®-UM, its gene expression profile (GEP) test to predict metastasis in patients diagnosed with uveal melanoma (UM). The paper, “Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study” was recently published in the Journal of Oncology. The prospective, multicenter CLEAR (Clinical Application of ... Read More

Older Entries »
Know your TYPE, Know your RISK
You’ve just been diagnosed with uveal melanoma, and it’s important to know that there is a test that can identify your tumor type—and the risk of your cancer spreading.

READ MORE
GETTING TESTED       Timing is Critical
To know your tumor type and risk, a biopsy must be taken BEFORE radiation treatment.

READ MORE
Talk to                 Your Doctor
Use this discussion guide to talk to your doctor about the genomic test to learn your tumor type, or CLASS.

DOWNLOAD PDF

Sign Up For Updates

Please leave this field empty.

Share on Facebook+1Share on Twitter

Share Your Stories

There's comfort in knowing you are not alone. If you or a loved one have experienced uveal melanoma and would like to help encourage others whose lives have been touched by this disease, please share your story with us.
Start Sharing